NXTC NextCure, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1661059 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY29.4%
TTM EPS YoY71.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-281.1%
ROA-166.2%
ROIC (approx.)-505.2%
Asset turnover—
Leverage & solvency
Liabilities / assets43.3%
Debt / equity0.00x
Current ratio2.31x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.04x
Accruals ratio7.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $44.92M | $41.49M | $47.93M | $54.20M | $50.19M |
| SG&A expense | $12.69M | $15.72M | $19.71M | $21.71M | $20.57M |
| Operating income | -$57.62M | -$59.75M | -$67.64M | -$75.91M | -$70.77M |
| Income tax | $0 | — | — | — | — |
| Net income | -$55.84M | -$55.65M | -$62.72M | -$74.73M | -$69.39M |
| EBITDA | -$55.42M | -$56.85M | -$63.94M | -$71.81M | -$66.47M |
| EPS (basic) | -19.65 | -23.88 | -2.25 | -2.69 | -2.51 |
| EPS (diluted) | -19.65 | -23.88 | -2.25 | -2.69 | -2.51 |
| Dividends declared per share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 2.84M | 2.33M | 27.84M | 27.74M | 27.62M |
| Balance sheet | |||||
| Cash & equivalents | $25.98M | $27.73M | $13.08M | $26.63M | $12.34M |
| Current assets | $43.75M | $71.81M | $112.72M | $163.98M | $227.82M |
| PP&E, net | $3.27M | $5.46M | $9.03M | $11.90M | $13.99M |
| Total assets | $50.18M | $80.86M | $128.04M | $184.16M | $242.39M |
| Current liabilities | $10.57M | $9.57M | $6.88M | $9.13M | $6.61M |
| Long-term debt | — | — | — | $0 | $0 |
| Total debt | — | — | — | $0 | $0 |
| Total liabilities | $15.24M | $15.39M | $13.62M | $16.63M | $9.00M |
| Shareholders' equity | $34.94M | $65.47M | $114.42M | $167.53M | $233.39M |
| Net debt | — | — | — | -$26.63M | -$12.34M |
| Shares outstanding | 3.51M | 2.33M | 27.90M | 27.77M | 27.68M |
| Cash flow statement | |||||
| Operating cash flow | -$49.61M | -$40.80M | -$52.97M | -$53.89M | -$57.28M |
| Capital expenditure | — | $474,000 | $820,000 | $2.12M | $2.36M |
| Free cash flow | — | -$41.28M | -$53.79M | -$56.00M | -$59.64M |
| Investing cash flow | $25.56M | $55.31M | $39.27M | $67.98M | $36.60M |
| Financing cash flow | $22.31M | $144,000 | $154,000 | $200,000 | -$3.27M |
| Depreciation & amortization | $2.20M | $2.90M | $3.70M | $4.10M | $4.30M |
| Stock-based compensation | $2.99M | $6.33M | $8.19M | $9.51M | $10.29M |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.